Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Priya Bahri

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Pharmacoepidemiology and Drug Safety|August 2, 2024
Studying the Impact of European Union Regulatory Interventions for Minimising Risks From Medicines: Lessons Learnt and RecommendationsThomas Goedecke, Liana Martirosyan, Nathalie Gault, et al.
Drug Safety|September 7, 2019
Correction to: Patient Registries: An Underused Resource for Medicines Evaluation : Operational proposals for increasing the use of patient registries in regulatory assessmentsPatricia McGettigan, Carla Alonso Olmo, Kelly Plueschke, et al.
Drug Safety|July 15, 2019
Patient Registries: An Underused Resource for Medicines Evaluation : Operational proposals for increasing the use of patient registries in regulatory assessmentsPatricia McGettigan, Carla Alonso Olmo, Kelly Plueschke, et al.
Drug Safety|February 15, 2023
What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey StudySonia Roldan Munoz, Douwe Postmus, Sieta T de Vries, et al.
Drug Safety|July 10, 2024
The STAR Compass to Guide Future Pharmacovigilance Based on a 10-Year Review of the Strengthened EU SystemPriya Bahri, Georgy Genov, Peter Arlett, et al.
Drug Safety|June 3, 2015
The ISoP CommSIG for Improving Medicinal Product Risk Communication: A New Special Interest Group of the International Society of PharmacovigilancePriya Bahri, Alexander N Dodoo, Brian D Edwards, et al.
Pharmacoepidemiology and Drug Safety|October 13, 2015
Benefit-Risk Assessment, Communication, and Evaluation (BRACE) throughout the life cycle of therapeutic products: overall perspective and role of the pharmacoepidemiologistChristine Radawski, Elaine Morrato, Kenneth Hornbuckle, et al.
Pharmacoepidemiology and Drug Safety|November 4, 2020
The utility of real-world evidence for benefit-risk assessment, communication, and evaluation of pharmaceuticals: Case studiesChristine A Radawski, Tarek A Hammad, Susan Colilla, et al.
Vaccine|November 4, 2019
Why we need more collaboration in Europe to enhance post-marketing surveillance of vaccinesMiriam Sturkenboom, Priya Bahri, Antonella Chiucchiuini, et al.
Journal of the American Geriatrics Society|May 17, 2024
Medicines for an aging population: The EMA perspective and policiesFrancesca Cerreta, Ewa Balkowiec Iskra, Amelia Cupelli, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Pharmacoepidemiology and Drug Safety|August 2, 2024
Studying the Impact of European Union Regulatory Interventions for Minimising Risks From Medicines: Lessons Learnt and RecommendationsThomas Goedecke, Liana Martirosyan, Nathalie Gault, et al.
Drug Safety|September 7, 2019
Correction to: Patient Registries: An Underused Resource for Medicines Evaluation : Operational proposals for increasing the use of patient registries in regulatory assessmentsPatricia McGettigan, Carla Alonso Olmo, Kelly Plueschke, et al.
Drug Safety|July 15, 2019
Patient Registries: An Underused Resource for Medicines Evaluation : Operational proposals for increasing the use of patient registries in regulatory assessmentsPatricia McGettigan, Carla Alonso Olmo, Kelly Plueschke, et al.
Drug Safety|February 15, 2023
What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey StudySonia Roldan Munoz, Douwe Postmus, Sieta T de Vries, et al.
Drug Safety|July 10, 2024
The STAR Compass to Guide Future Pharmacovigilance Based on a 10-Year Review of the Strengthened EU SystemPriya Bahri, Georgy Genov, Peter Arlett, et al.
Drug Safety|June 3, 2015
The ISoP CommSIG for Improving Medicinal Product Risk Communication: A New Special Interest Group of the International Society of PharmacovigilancePriya Bahri, Alexander N Dodoo, Brian D Edwards, et al.
Pharmacoepidemiology and Drug Safety|October 13, 2015
Benefit-Risk Assessment, Communication, and Evaluation (BRACE) throughout the life cycle of therapeutic products: overall perspective and role of the pharmacoepidemiologistChristine Radawski, Elaine Morrato, Kenneth Hornbuckle, et al.
Pharmacoepidemiology and Drug Safety|November 4, 2020
The utility of real-world evidence for benefit-risk assessment, communication, and evaluation of pharmaceuticals: Case studiesChristine A Radawski, Tarek A Hammad, Susan Colilla, et al.
Vaccine|November 4, 2019
Why we need more collaboration in Europe to enhance post-marketing surveillance of vaccinesMiriam Sturkenboom, Priya Bahri, Antonella Chiucchiuini, et al.
Journal of the American Geriatrics Society|May 17, 2024
Medicines for an aging population: The EMA perspective and policiesFrancesca Cerreta, Ewa Balkowiec Iskra, Amelia Cupelli, et al.
Pageof 4